7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $3M | -$15M | 36.3% | -446.7% | -$15M | $13000 | $9M |
| 2024 | $3M | -$15M | 44.1% | -476.9% | -$13M | $161000 | $8M |
| 2023 | $3M | -$15M | 40.3% | -482.4% | -$13M | — | $11M |
| 2022 | $3M | -$17M | 46.8% | -542.6% | -$15M | — | $24M |
| 2021 | $4M | -$10M | 53.0% | -235.0% | -$13M | — | $26M |
| 2020 | $4M | -$4M | 63.2% | -107.1% | -$4M | — | $4M |
| 2019 | $2M | -$5M | 32.2% | -294.0% | -$2M | — | — |
How the market has priced ICCM against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, IceCure Medical Ltd.'s revenue has declined 2.7% per year. These are computed facts, not advice.
As of FY2025, IceCure Medical Ltd. reported $13000 of total debt against $9M of cash.
In FY2025, gross margin was 36.3%, operating margin -446.7%, and net margin -445.6%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.